PCOS Renamed: New Name Reflects Broader Health Impacts

Polycystic ovary syndrome (PCOS), a condition affecting 170 million women worldwide and a leading cause of infertility, has been renamed polyendocrine metabolic ovarian syndrome (PMOS). This significant change was announced on May 12, 2026, at a medical meeting.

The new name was selected by a global coalition of patients, clinicians, and medical organizations to more accurately represent the condition's extensive hormonal and metabolic influences. This initiative aims to rectify the common misconception that PCOS exclusively involves ovarian cysts, a feature not present in all patients.

The focus on ovarian cysts has historically led to delayed diagnoses and fragmented care. The new name, PMOS, is intended to enhance detection, treatment strategies, and overall comprehension of the disorder. This consensus was built upon extensive global input, including over 14,000 survey responses from patients and health professionals.

Symptoms of PMOS encompass irregular or absent menstrual cycles, infertility, pregnancy complications, excess hair growth, acne, mood disturbances like anxiety and depression, weight gain, obesity, diabetes, insulin resistance, and cardiovascular disease. While not curable, symptoms are manageable through medication and lifestyle adjustments.

A transition to the new terminology is planned over the next three years, involving integration into health systems, clinical guidelines, and professional training.